Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CONCORD HEALTHCARE GROUP CO., LTD.
美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

VOLUNTARY ANNOUNCEMENT
ANNOUNCEMENT ON THE PROGRESS OF PROTON THERAPY BUSINESS

This announcement is made by the board of directors (the "**Board**") of Concord Healthcare Group Co., Ltd. (the "**Company**") on a voluntary basis.

The Board is pleased to announce that the proton therapy center of the Company's subsidiary, Guangzhou Concord Cancer Center (hereinafter referred to as the "**Guangzhou Hospital Proton Center**") has been officially operational for one year since 16 December 2024. The Company places high importance on the development of clinical capabilities at the proton therapy center. It remains committed to strengthening collaborative research with internationally advanced medical institutions, keeping pace with global proton therapy technology, and continuously enhancing its standards of diagnosis and treatment through measures such as introducing high-end medical talents, and intensifying technological research and development and academic exchanges. As of now, the clinical service capacity of the Guangzhou Hospital Proton Center has been fully validated, with all operational indicators performing well.

All four proton therapy rooms at the Guangzhou Hospital Proton Center have been put into use. To date, the center has provided proton therapy services to 550 patients and have exceeded 80 newly treated patients in a single month, demonstrating a continuous enhancement in service capacity. The center serves patients from 31 provincial-level administrative regions across China as well as over 20 countries and regions worldwide. The age of patients receiving proton therapy ranges from 1 to 91 years old. In July 2025, the Guangzhou Hospital Proton Center completed the first proton therapy treatment in China for a patient with ocular choroidal malignant melanoma.

During this year, the steady advancement of the Company's proton therapy business has further improved the Company's layout in the field of precision oncology treatment, and enhanced its core competitiveness in the high-end medical services sector. Moving forward, the Company will continue to optimize service processes and improve diagnosis and treatment efficiency, with the aim of delivering high-quality and precise proton therapy services to more oncology patients.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, December 30, 2025

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. Song Qingbao and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.